ReviewCureus2021
Correlation of Coronary Artery Disease and Left Ventricular Hypertrophy.
Review in Cureus, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 19 citations in OpenAlex.
- Determinants of left ventricular hypertrophy in a cohort attending a medical clinic: A comparative analysis stratified by sex.PLOS global public health · 2026Article
- Twin pairs discordant for incident coronary artery disease reveal epigenetic and transcriptomic differences by gene region.Molecular genetics and genomics : MGG · 2025Article
- Predictors of Acute Myocardial Infarction: A Machine Learning Analysis After a 7-Year Follow-Up.Clinics and practice · 2025Article
- Cardiac Magnetic Resonance Imaging in Diagnostics and Cardiovascular Risk Assessment.Diagnostics (Basel, Switzerland) · 2025Review
- Understanding the hidden burden: prevalence and factors linked to left ventricular hypertrophy in hypertensive patients receiving care in Harari region, Ethiopia.Frontiers in cardiovascular medicine · 2025Article
- Cardiac hypertrophy in polycythemia vera: A case report and review of literature.World journal of cardiology · 2024Article
- AI-based cluster analysis enables outcomes prediction among patients with increased LVM.Frontiers in cardiovascular medicine · 2024Article
- Ectasia and slow flow phenomena of coronary artery related to apical hypertrophic cardiomyopathy.Clinical case reports · 2023Article
- Metformin Attenuates Cardiac HypertrophyFrontiers in pharmacology · 2022Article
- From Iron Metabolism to Ferroptosis: Pathologic Changes in Coronary Heart Disease.Oxidative medicine and cellular longevity · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ischemic heart disease (IHD) is the leading cause of death worldwide, and it is defined as an imbalance between myocardial oxygen supply and demand. Coronary artery disease (CAD) and left ventricular hypertrophy (LVH) are two common causes of IHD that independently result in myocardial ischemia. CAD decreases myocardial blood and oxygen supply whereas LVH increases myocardial oxygen demand. The coexistence of both CAD and LVH results in a significant increase in oxygen demand while simultaneously lowering oxygen supply. Since hypertension is a shared predisposing condition for both CAD and LVH, the left ventricular (LV) mass on noninvasive echocardiography can reflect on the severity of coronary artery stenosis. In clinical practice, it can help physicians decide whether to perform invasive cardiac catheterization to visualize the extent of the coronary block. Although, both CAD and LVH are directly proportional to mortality risk, the addition of eccentric LVH can further increase morbidity and mortality due to myocardial infarction. Therefore, the latest management of both the acute and chronic phases of CAD places an increased emphasis on controlling the predisposing factors to prevent or reverse LVH. For example, angiotensin-converting enzyme inhibitors and diuretics reduce LV mass by lowering the cardiac preload and afterload. This article aims to investigate the deleterious effects of the collaboration between CAD and LVH, establish a causal relationship, and explore the new prevention and management strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.